

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-2. (Canceled)

3. (Previously Presented) An expression vector comprising a polynucleotide of claim 18 operably linked to an expression control sequence.

4. (Original) A host cell transformed or transfected with an expression vector according to claim 3.

5.-10. (Canceled)

11. (Previously Presented) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component consisting of a polynucleotide according to claim 18.

12.-17. (Canceled)

18. (Previously Presented) An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) the contiguous nucleotide sequence provided in SEQ ID NO:302, or a contiguous nucleotide sequence encoding the polypeptide of SEQ ID NO:305;

(b) the contiguous nucleotide sequence provided in SEQ ID NO:303, or a contiguous nucleotide sequence encoding the polypeptide of SEQ ID NO:306; and

(c) the full length complement of a sequence according to (a) or (b).